{"prompt": "['Neither the sponsor nor the CRO is financially responsible for further testing or', 'treatment of any medical condition that may be detected during the screening process.', 'In addition, in the absence of specific arrangements, neither the sponsor nor the CRO is', \"financially responsible for further treatment of the patient's disease.\", '15.7', 'Patient Confidentiality', 'All laboratory specimens, evaluation forms, reports, and other records will be identified', 'in a manner designed to maintain patient confidentiality. All records will be kept in a', 'secure storage area with limited access. Clinical information will not be released', \"without the written permission of the patient (or the patient's legal guardian), except as\", 'necessary for monitoring and auditing by the sponsor, its designee, the US FDA or other', 'local regulatory authorities, or the IRB/IEC.', 'The investigator and all employees and coworkers involved with this study may not', 'disclose or use for any purpose other than performance of the study any data, record, or', 'other unpublished, confidential information disclosed to those individuals for the', 'purpose of the study. Prior written agreement from the sponsor or its designee must be', 'obtained for the disclosure of any said confidential information to other parties.', '15.8', 'Future Use of Stored Specimens and Other Identifiable Data', 'Residual blood samples collected for pharmacokinetic analysis may be maintained after', 'the study is complete. Patients will provide informed consent form for the future use of', 'his/her samples. The sponsor or designee will maintain the samples up to 10 years', 'following the completion of the study for pharmacokinetic analysis purposes only.', 'Confidentiality will be protected for any future studies with the stored samples or data', 'de-identified (identified by patient identification number only). Genetic testing will not be', 'performed.', 'Intra-Cellular Therapies, Inc. Confidential', '68 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['16 DATA HANDLING AND RECORD KEEPING', 'Prior to beginning the study, the investigator will be asked to comply with ICH E6(R1)', '8.2 and Title 21 of the US Code of Federal Regulations (CFR) by providing the following', 'essential documents, including but not limited to:', 'IRB/IEC approval', 'Original investigator-signed investigator agreement page of the protocol', 'Form FDA 1572, fully executed, and all updates on a new fully executed', 'Form FDA 1572', 'Curriculum vitae for the investigator and each subinvestigator listed on', 'Form FDA 1572', 'Financial disclosure information to allow the sponsor to submit complete', 'and accurate certification or disclosure statements required under 21 CFR', '54. In addition, the investigators must provide to the sponsor a commitment', 'to promptly update this information if any relevant changes occur during the', 'course of the investigation and for 1 year after study completion.', 'IRB/IEC-approved informed consent, samples of site advertisements for', 'recruitment for this study, and any other written information regarding this', 'study that is to be provided to the patient or legal guardian, and', 'Laboratory certifications and normal ranges for any local laboratories used', 'by the study site, in accordance with 42 CFR 493', 'As part of the responsibilities assumed by participating in the study, the investigator', 'agrees to maintain adequate case histories for the patients treated as part of the', 'research under this protocol. The investigator agrees to maintain accurate eCRFs and', 'source documentation as part of the case histories. These source documents may', 'include records of screening assessments such as the M.I.N.I., laboratory reports, and', 'ECG strips.', 'After database lock, each study site will receive a CD-ROM containing all of their study', 'site-specific eCRF data as entered into the EDC, including full discrepancy and audit', \"history. Additionally, a CD-ROM copy of all of the study site's data will be created and\", 'sent to the sponsor for storage. The CRO will maintain a duplicate CD-ROM copy for', 'their records. In all cases, patient initials will not be collected or transmitted to the', 'sponsor.', 'Intra-Cellular Therapies, Inc. Confidential', '69 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['16.1', 'Data Management Responsibilities', 'Clinical data management will be performed in accordance with applicable ITI standards', 'and data cleaning procedures to ensure the integrity of the data, e.g., removing errors', 'and inconsistencies in the data. Adverse events and concomitant medication terms will', 'be coded using MedDRA, an internal validated medication dictionary.', '16.2', 'Data Capture Methods', 'Clinical study site personnel will enter patient data into electronic data capture (EDC).', 'All eCRF fields are to be filled in. If an item is not available or is not applicable, this fact', 'should be indicated. Blank fields should not be present unless otherwise directed. The', 'analysis data sets will be a combination of these data and data from other sources (e.g.,', 'laboratory data).', '16.3', 'Types of Data', 'Types of data that will be collected includes efficacy outcome assessments, safety', 'outcome assessments, and pharmacokinetic assessments.', '16.4', 'Schedule and Content of Reports', 'The sponsor or designee will be responsible for clinical monitoring plans and reports,', 'safety monitoring plans, data management plans, statistical analysis plans and the', 'clinical study report. Masking procedures and breaking the blind are described in', 'Sections 5.4.2 and 5.4.3, respectively.', '16.5', 'Study Records Retention', 'Essential documents should be retained until at least 2 years after the last approval of a', 'marketing application in an ICH region and until there are no pending or contemplated', 'marketing applications in an ICH region or at least 2 years have elapsed since the', 'formal discontinuation of clinical development of the investigational product. These', 'documents should be retained for a longer period, however, if required by the applicable', 'regulatory requirements or by an agreement with the sponsor. It is the responsibility of', 'the sponsor to inform the investigator/institution as to when these documents no longer', 'need to be retained.', '16.6', 'Protocol Deviations', \"The investigator or designee must document and explain in the patient's source\", 'documentation any deviation from the approved protocol. The investigator may', 'implement a deviation from, or a change of, the protocol to eliminate an immediate', 'hazard to study patients without prior IRB/IEC approval. As soon as possible after such', 'an occurrence, the implemented deviation or change, the reasons for it, and any', 'proposed protocol amendments should be submitted to the IRB/IEC for review and', 'approval, to the sponsor for agreement, and to the regulatory authorities, if required.', 'Intra-Cellular Therapies, Inc. Confidential', '70 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}